Stockreport

Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle ce...

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months fixed-duration ibrutinib therapy Both ibrutinib-based regimens, tra [Read more]